medigraphic.com
ISSN 2683-1678 (Impreso)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2020, Número 4

<< Anterior Siguiente >>

Rev Latin Infect Pediatr 2020; 33 (4)


Diferencias entre niños y adultos por el nuevo coronavirus 2019, SARS-CoV-2/COVID-19

Benavides RI; López ME, López LP

Idioma: Español
Referencias bibliográficas: 38
Paginas: 165-173
Archivo PDF: 226.18 Kb.


RESUMEN

En diciembre de 2019 desde China se reportaron casos que fueron llamados inicialmente «neumonía de origen desconocido»; el agente causal de esta neumonía es un nuevo coronavirus, el cual fue nombrado coronavirus 2 del síndrome respiratorio agudo severo (SARS-CoV-2). El término COVID-19 se utiliza para definir la enfermedad clínica causada por SARS-CoV-2. En niños la enfermedad parece ser más leve que en los adultos, por lo que se han propuesto varias hipótesis para explicar este comportamiento. Sin embargo, los lactantes, niños y adolescentes con comorbilidades tienen cuadros relativamente más severos. En esta revisión presentamos las diferencias entre niños y adultos con COVID-19, las manifestaciones clínicas (enfatizando en el síndrome postinflamatorio multisistémico), las pruebas diagnósticas y el papel de los niños en la transmisión comunitaria de la infección.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323 (13): 1239-1242.

  2. Dong Y, Mo X, Hu Y et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics. 2020. doi: 10.1542/peds.2020-0702.

  3. Liu W, Zhang Q, Chen J, Xiang R, Song H, Shu S et al. Detection of Covid-19 in children in early january 2020 in Wuhan, China. N Engl J Med. 2020; 382 (14): 1370-1371.

  4. Singh T, Heston SM, Langel SN, Blasi M, Hurst JH, Fouda GG et al. Lessons from COVID-19 in children: key hypotheses to guide preventative and therapeutic strategies. Clin Infect Dis [Internet]. 2020; ciaa547. Available in: https://doi.org/10.1093/cid/ciaa547

  5. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020; 395 (10237): 1607-1608.

  6. Hamiel U, Kozer E, Youngster I. SARS-CoV-2 rates in BCG-vaccinated and unvaccinated young adults. JAMA. 2020; 323 (22): 2340-2341. doi: 10.1001/jama.2020.8189.

  7. Fang F, Luo XP. Facing the pandemic of 2019 novel coronavirus infections: the pediatric perspectives. Zhonghua Er Ke Za Zhi. 2020; 58 (0): E001.

  8. Garazzino S, Montagnani C, Donà D, Meini A, Felici E, Vergine G et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Euro Surveill. 2020; 25 (18): 2000600. doi: 10.2807/1560-7917.ES.2020.25.18.2000600.

  9. Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian Pediatric Intensive Care Units. JAMA Pediatr. 2020. doi: 10.1001/jamapediatrics.2020.1948.

  10. World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19. 2020. WHO reference number: WHO/2019-nCoV/Sci_Brief/Multisystem_Syndrome_Children/2020.1

  11. Nowak MD, Sordillo EM, Gitman MR, Paniz Mondolfi AE. Co-infection in SARS-CoV-2 infected patients: where are influenza virus and rhinovirus/enterovirus? J Med Virol. 2020: 10.1002/jmv.25953.

  12. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA. 2020; 323 (20): 2085-2086.

  13. Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA. 2020; 323 (22): 2249-2251.

  14. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatr Pulmonol. 2020; 55 (5): 1169-117.

  15. Zimmermann P, Curtis N. COVID-19 in children, pregnancy and neonates: a review of epidemiologic and clinical features. Pediatr Infect Dis J. 2020; 39 (6): 469-477.

  16. Lopez-Medina E, Ardura MI, Siegel JD, Brock E, Sánchez PJ. 2009 influenza A in infants hospitalized at younger than 6 months. J Pediatr. 2012; 160 (4): 626-631.e1.

  17. OMS. Ensayo clínico “Solidaridad” sobre tratamientos contra la COVID-19. 2020. Disponible en: https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments

  18. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC et al. Remdesivir for the treatment of COVID-19 - Preliminary Report. N Engl J Med. 2020: NEJMoa2007764.

  19. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395 (10236): 1569-1578.

  20. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020; 382 (19): 1787-1799.

  21. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC et al. Infectious diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020: ciaa478.

  22. Anonymous Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia. Available in: https://www.roche.com/investors/updates/inv-update-2020-07-29.htm

  23. Cheng Y, Wong R, Soo YO et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005; 24 (1): 44-46.

  24. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020; 323 (16): 1582-1589.

  25. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020; 324 (5): 460-470.

  26. Ranieri VM, Pettilä V, Karvonen MK, Jalkanen J, Nightingale P, Brealey D et al. Effect of intravenous interferon β-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: a randomized clinical trial. JAMA. 2020.

  27. Saavedra Trujillo CH. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-CoV-2/COVID 19 en establecimientos de atención de la salud. Recomendaciones basadas en consenso de expertos e informadas en la evidencia, Infectio. 2020; 24 (3): 1-153.

  28. Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science. 2020; 368 (6489): 395-400.

  29. Cauchemez S, Valleron AJ, Boelle PY, Flahault A, Ferguson NM. Estimating the impact of school closure on influenza transmission from Sentinel data. Nature. 2008; 452 (7188): 750-754. doi: 10.1038/nature06732.12.

  30. Litvinova M, Liu QH, Kulikov ES, Ajelli M. Reactive school closure weakens the network of social interactions and reduces the spread of influenza. Proc Natl Acad Sci U S A. 2019; 116 (27): 13174-13181. doi: 10.1073/pnas.1821298116.

  31. Armitage R, Nellums LB. Considering inequalities in the school closure response to COVID-19. Lancet Glob Health. 2020; 8 (5): e644. doi: 10.1016/S2214-109X(20)30116-9.

  32. COVID-19 in schools-the experience in NSW. National Centre for Immunisation Research and Surveillance. New South Wales, Australia. April 26, 2020.

  33. Posfay-Barbe KM, Wagner N, Gauthey M, Moussaoui D, Loevy N, Diana A et al. COVID-19 in children and the dynamics of infection in families. Pediatrics. 2020; 146 (2): e20201576.

  34. Lee B, Raszka WV Jr. COVID-19 transmission and children: the child is not to blame. Pediatrics. 2020; 146 (2): e2020004879.

  35. Wu Q, Xing Y, Shi L, Li W, Gao Y, Pan S et al. Coinfection and other clinical characteristics of COVID-19 in children. Pediatrics. 2020; 146 (1): e20200961.

  36. Jiehao C, Jin X, Daojiong L, Zhi Y, Lei X, Zhenghai Q et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020; 71 (6): 1547-1551.

  37. Jones TC, Jones TC, Mühlemann B, Veith T, Biele G, Zuchowski M, Hoffmann J et al. An analysis of SARS-CoV-2 viral load by patient age. medRxiv. 2020.

  38. Mayo Clinic. Vacuna contra la COVID-19 (coronavirus): obtén la información verdadera. 2020. Disponible en: www.mayoclinic.org/es-es/coronavirus-vaccine/art-20484859




2020     |     www.medigraphic.com